key: cord-0973346-l1jyz8sr
authors: Li, Linghua; Liang, Yuanhao; Hu, Fengyu; Yan, Huanchang; Li, Yueping; Xie, Zhiwei; Huang, Liping; Zhao, Jianhui; Wan, Zhengwei; Wang, Haiying; Shui, Jingwei; Cai, Weiping; Tang, Shixing
title: Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients
date: 2020-09-28
journal: Virology
DOI: 10.1016/j.virol.2020.09.008
sha: 24ec682d4100fa2c4da7e1b505689184f15a9a11
doc_id: 973346
cord_uid: l1jyz8sr

BACKGROUND: SARS-CoV-2 is a novel coronavirus and the cause of COVID-19. More than 80% of COVID-19 patients exhibit mild or moderate symptoms. In this study, we investigated the dynamics of viral load and antibodies against SARS-CoV-2 in a longitudinal cohort of COVID-19 patients with severe and mild/moderate diseases. METHODS: Demographic and clinical information were obtained. Serial samples of blood, nasal and pharyngeal and anal swabs were collected at different time points post-onset. SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies were measured by qRT-PCR and immunoassays, respectively. RESULTS: Respiratory SARS-CoV-2 RNA was detectable in 58.0% (58/100) COVID-19 patients upon admission and lasted for a median of 13 days post-onset. In addition, 5.9% (1/17) and 20.2% (19/94) of the blood and anal swab specimens were positive for SARS-CoV-2 RNA, respectively. Anal viral RNA was more frequently detected in the patients who were positive for viral RNA in the respiratory samples upon admission. Specific anti-SARS-CoV-2 antibody developed within two weeks after onset, reached peak approximately 17 days post-onset and then maintained at relatively high level up to 50 days we analyzed in most patients. However, the levels of antibodies were variable among the patients. High titers of antibodies appeared to be associated with the severity of the disease. Furthermore, viral proteins from different sources showed significant difference of serological sensitivity especially during the first week post-onset. CONCLUSIONS: Our results indicate rapid clearance or self-elimination of viral RNA in about half of the COVID-19 patients upon admission. Viral RNA shedding of SARS-CoV-2 occurred in multiple tissues including the respiratory system, blood, and intestine. Variable levels of specific anti-SARS-CoV-2 antibody may be associated with disease severity. These findings have shed light on viral kinetics and antibody response in COVID-19 patients and provide scientific evidence for infection control and patient management.

Data were analyzed using R software, version 3.5.2 (R Foundation for Statistical Computing). 165

Continuous variables were summarized as the medians and interquartile ranges (IQR) and 166 compared using Mann-Whitney U test whereas categorical variables were expressed as 167 counts and percentages and compared using Chi-square analysis or Fisher's exact test as 168 time from illness onset as fixed variate were adapted to estimate the longitudinal slopes of 170 anti-SARS-CoV-2 antibody titers. The time period of viral RNA shedding was defined as the 171 interval from illness onset to the time when two consecutive throat-swab samples were 172 negative for SARS-CoV-2 RNA (at least 24 hours apart). Mild and moderate COVID-19 173 patients were put together as a group for further analysis while severe and critical patients 174 were treated as the patients with severe disease. P < 0.05 was considered statistically 175 significant. 176

Detection dynamics of SARS-CoV-2 RNA 179

The median age of COVID-19 patients was 51.0 years (IQR 37.8-63.0) and 51.0% of them 180 were men. 77.0% and 55.0% had fever and cough, respectively (Table 1) . Among these 181 patients, 69.0% had the history of visiting Hubei province where COVID-19 epidemic started. 182

The median durations from illness onset to hospital admission were 4.5 days (IQR 3.0-7.0) 183 (Table1). Two patients, #13 and #15, were negative for SARS-CoV-2 RNA upon admission, 184 and did not show any antibody response against both SARS-CoV-2 NP, S1 or RBD proteins 185 thereafter ( Fig. 1E and F, Table S1 ). They may be probably misdiagnosed as SARS-CoV-2 186 infection due to false positive detection for SARS-CoV-2 RNA or showed delayed antibody (Table 1 and S2). The difference in the clinical findings between the two groups 218 includes more frequent major symptoms such as fever (91.4% vs 60%) and cough (65.5% vs 219 42.5%), delayed admission (6 vs 3 days) and less frequent anal positivity for SARS-CoV-2 220 RNA (18.5% vs 23.7%, Table 1 ). 221

In addition, the antibodies against SARS-CoV-2 NP and S1 or RBD proteins were analyzed 223 by ELISA, and the temporal profiles of anti-SARS-CoV-2 antibodies obtained by ELISA 224 were similar to those of LISA ( Fig. 2, 3 , Table 3 ). Furthermore, the seroconversion for 225 anti-S1 or RBD were earlier and the antibody titers were higher than for anti-NP (Fig. 2, 3) . 226

In addition, similar antibody profiles were observed between the patients with severe and 227 mild/moderate diseases although the seroconversion for anti-S1 and anti-RBD antibody was 228 slightly earlier than for anti-NP antibody ( Table 4) . 229 of anti-SARS-CoV-2 antibodies. We compared the time and percentage of seroconversion for 233 anti-SARS-CoV-2 antibodies determined by different SARS-CoV-2 antigens in ELISA 234 system (Table 3 Of note, the patients with detectable SARS-CoV-2 RNA upon admission showed one more 273 specimens for 3 more days (Table 2) . Furthermore, the extended detection of viral RNA in the 275 respiratory samples could further increase the detection of viral RNA in multiple tissues 276 including blood (14.3%) and intestine (30.2%). Compared with the total COVID-19 patients 277 analyzed in our study, SARS-CoV-2 RNA was only detected in 5.9% of the blood samples 278 and 20.2% of the anal swab samples (Table 1) These results suggest that titration of anti-SARS-CoV-2 antibody is necessary and useful for 303 monitoring disease progress and severity. 304 305 When we originally analyzed 17 patients with mild or moderate COVID-19, we found that 306 anal viral RNA was more frequently detected in the patients with low titer of 307 anti-SARS-CoV-2 antibodies (data not shown). The difference of viral RNA detection was 308 also observed when more COVID-19 patients with both severe and mild/moderate diseases 309 were analyzed. However, the association between viral RNA detection in anal samples and 310 the titers of antibody of SARAS-CoV-2 was not statistically significant (Table 1) . 311 Furthermore, anal viral RNA was more frequently detected in the COVID-19 patients who 312 were still positive for SARS-CoV-2 RNA upon admission (Table 2) proteins or the antigens from different sources. In general, SARS-CoV-2 S1 subunit or RBD 325 proteins are better than NP for sensitive detection of anti-SARS-CoV-2 antibodies during the 326 early stages of disease. 327 328 One major limit of our study is that we only detected the total antibody against SARS-CoV-2. 329

We did not measure the neutralizing antibody and did not evaluate the association between 330 the titers of neutralizing antibody and virus shedding in the COVID-19 patients. Our in-house 331 LISA was better for quantitating the levels of anti-SARS-CoV-2 antibodies than the 332 traditional ELISA. LISA results for anti-SARS-CoV-2 NP antibody was used to classify the 333 COVID-19 patients into high and low titers of antibody in our study. However, we should use 334 both anti-NP and anti-RBD/anti-S1 antibodies for the classification. Unfortunately, we failed 335 to develop LISA for anti-RBD/anti-S1 probably due to the high glycosylation of these two 336 the total IgM or IgG were captured by anti-IgM antibody or protein G instead of a 338 SARS-CoV-2 protein; therefore, we measured the proportion of a patient's' IgM or IgG that is 339 anti-SARS-CoV-2. The best method to detect antibodies against SARS-CoV-2 proteins is to 340 coat the plate with specific SARS-CoV-2 proteins. LISA, luciferase immunosorbent assay; ELISA, enzyme linked immunoassay; NP, 48 nucleocapsid proteins.; RBD, receptor-binding domain; S1, spike protein S1 subunit; nucleocapsid proteins.; RBD, receptor-binding domain; S1, spike protein S1 subunit;

371 clearance and delayed antibody response in a case of COVID-19 with a history of 439 co-infection with HIV-1 and HCV

Detection of

SARS-CoV-2 in Different Types of Clinical Specimens

Gastrointestinal 446 Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a

Systematic Review and Meta-analysis

Prolonged 451 presence of SARS-CoV-2 viral RNA in faecal samples. The lancet. Gastroenterology RT-qPCR solutions for SARS-CoV-2 detection

Positive RT-PCR Test Results 463 in Patients Recovered From COVID-19

Virological assessment of hospitalized patients with COVID-2019

Organ distribution 469 of severe acute respiratory syndrome (SARS) associated coronavirus